Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Decloro dihydroxy difluoro ethycloprostenolamide is a synthetic small molecule prostaglandin analog, specifically an ethyl amide derivative of tafluprost. It is primarily utilized as an active ingredient in over-the-counter cosmetic eyelash and eyebrow enhancement serums, such as RevitaLash Advanced. The compound acts as an agonist at prostaglandin receptors, which is believed to prolong the anagen (active growth) phase of the hair follicle cycle, leading to increased length and density of lashes. Despite its widespread use in the cosmetic industry, it is not approved as a pharmaceutical drug for this indication. In 2026, the European Scientific Committee on Consumer Safety (SCCS) raised significant safety concerns regarding its potent pharmacological activity and potential for reproductive toxicity, concluding it could not be considered safe for cosmetic use. Side effects are similar to prescription prostaglandin analogs (like bimatoprost) and include iris pigmentation changes, eye irritation, and periorbital fat loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on decloro dihydroxy difluoro ethycloprostenolamide.